In August 1995, Telios Pharmaceuticals was acquired by Integra LifeSciences Holdings Corporation in affective merger of the smaller firm somewhat struggling atthe time. Involved in SBIR soon afer its founding, Telios Pharmaceuticals, Inc. had been engaged in the discovery and development of its matrix peptide technology. Both companies had been working on tissue repair. Integra iactively developing Integra Artificial Skin and other projects to support the body's natural abilities to repair and heal its own tissues and organs, while Telios pioneered development of therapeutic products based on extracellular matrix technology, with potential applications in tissue repair, cardiovascular diseases, fibrotic diseases and osteoporosis.
